Research programme: therapeutic peptides - PeptiMimesis/Ipsen

Drug Profile

Research programme: therapeutic peptides - PeptiMimesis/Ipsen

Latest Information Update: 25 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PeptiMimesis Pharma
  • Developer Domain Therapeutics; Ipsen; PeptiMimesis Pharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action Dimerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Immunological disorders

Most Recent Events

  • 07 Oct 2016 Preclinical trials in Cancer in France (unspecified route) (Ipsen annual report 2015; 9205113)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top